Sven Löffeler, Helena Bertilsson, Christoph Müller, Kirsti Aas, Hege Sagstuen Haugnes, Bjørg Aksnessaether, Maiju Pesonen, Kristian Thon, Torgrim Tandstad, Teemu Murtola, Mads Hvid Poulsen, Tobias Nordstrøm, Maria Nyre Vigmostad, Fredrik Ottosson, Karin Holmsten, Ola Christiansen, Marit Slaaen, Erik Skaaheim Haug, Anne Holck Storås, Lars Asphaug, Antti Rannikko, Klaus Brasso
BACKGROUND: Older men (aged ≥75 years) with high risk, non-metastatic prostate cancer (PCa) are increasingly treated with curative therapy (surgery or radiotherapy). However, it is unclear if curative therapy prolongs life and improves health-related quality of life (HRQoL) in this age group compared to conservative therapy, which has evolved considerably during the last decade. STUDY DESIGN: The Scandinavian Prostate Cancer Group (SPCG) 19/Norwegian Get-Randomized Research Group-Prostate (GRand-P) is a randomised, two-armed, controlled, multicentre, phase III trial carried out at study centres in Norway, Denmark, Finland, and Sweden...
March 12, 2024: BJU International